NATURAL ALTERNATIVES INTERNATIONAL INC
For the period ended Jun 30, 2024. Filed Sep 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 27, 2024
Contents
SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS
Certain statements in this report, including information incorporated by reference, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect current views about future events and financial performance based on certain assumptions. They include opinions, forecasts, intentions, plans, goals, projections, guidance, expectations, beliefs, or other statements that are not statements of historical fact. Words such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “approximate,” “predict,” “forecast,” “project,”, “future”, or “likely”, or the negative or other variation of such words, and similar expressions may identify a statement as a forward-looking statement. Any statements that refer to projections of our future financial performance, our anticipated growth and trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism or pessimism about future operating results, are forward-looking statements. Forward-looking statements in this report may include statements about:
| • | our ability to develop market acceptance for and increase sales of new products, develop relationships with new customers and maintain or improve existing customer relationships; |
| • | future financial and operating results, including projections of net sales, revenue, income or loss, net income or loss per share, profit margins, expenditures, liquidity, and other financial items; |
| • | the sufficiency of our available cash, cash equivalents, and potential cash flows from our operations to fund our working capital and capital expenditure needs through the next 12 months and longer; |
| • | the future adequacy and intended use of our facilities; |
| • | future customer orders and the timing thereof; |
| • | our ability to price our products to achieve profit margin targets, especially in the current volatile raw material and labor environment; |
| • | our ability to maintain or increase our patent and trademark licensing revenues; |
| • | our ability to improve operating efficiencies, manage costs and business risks, and improve or maintain profitability; |
| • | sources, availability and quality of raw materials, including the limited number of suppliers of beta-alanine meeting our quality requirements; |
| • | our ability to attract and retain sufficient labor to successfully execute our business strategies and achieve our goals and objectives; |
| • | inventory levels, including the adequacy of quality raw material and other inventory levels to meet future customer demand; |
| • | our ability to protect our intellectual property; |
| • | future economic and political conditions; |
| • | currency exchange rates and their effect on our results of operations (including amounts that we may reclassify as earnings), the availability of foreign exchange facilities, our ability to effectively hedge against foreign exchange risks and the extent to which we may seek to hedge against such risks; |
| • | the outcome of litigation, regulatory and tax matters we may become involved in, the costs associated with such matters and the effect of such matters on our business and results of operations; |
| • | potential manufacturing and distribution channels, product returns, and potential product recalls; |
| • | the impact of external factors on our business and results of operations, especially, for example, variations in quarterly net sales from seasonal and other external factors; |
| • | our ability to operate within the standards set by the U.S. Food and Drug Administration’s (FDA) Good Manufacturing Practices (GMPs); |
| • | the adequacy of our financial reserves and allowances; |
| • | the impact of accounting pronouncements and our adoption of certain accounting guidance; and |
| • | other assumptions described in this Report underlying or relating to any forward-looking statements. |
The forward-looking statements in this Report speak only as of the date of this Report based on information available to us at that time and caution should be taken not to place undue reliance on any such forward-looking statements. Forward-looking statements are subject to certain future events, risks, and uncertainties that are or may be outside of our control. When considering forward-looking statements, you should carefully review the risks, uncertainties and other cautionary statements in this Report as they identify certain important factors that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These factors include, among others, the risks described under Item 1A of Part I and elsewhere in this report, as well as in other reports and documents we have filed and will file with the United States Securities and Exchange Commission (SEC).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.